[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555099":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":35,"responsibleParty":52,"collaborators":54,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":20,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":20,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":20,"overallStatus":38,"whyStopped":20,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"First Affiliated Hospital of Chongqing Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Radiotherapy combined with ripretinib group","EXPERIMENTAL","Radiotherapy (50-70Gy\u002F25-30f)+ ripretinib(150mg QD)",[13],"Radiation: simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","simultaneous integrated boost intensity-modulated radiation therapy combined with ripretinib","A cumulative radiation dose of 50 to 70 Gy is administered in 25-30 fractions, 5 fractions per week, to the target lesion(s).\n\nripretinib: oral 150mg QD",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Jun Zhang","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Jun Zhang, MD","CONTACT","+86 136 1766 6067","zjun2323@sina.cn",{"name":32,"role":28,"phone":33,"phoneExt":20,"email":34},"Longhao Li, MD","+86 183 7580 7001","llh@hospital.cqmu.edu.cn",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"The First Affiliated Hospital of Chongqing Medical University","RECRUITING","Chongqing","Chongqing Municipality","400016","China","CN",{"type":45,"coordinates":46},"Point",[47,48],106.55771,29.56026,{"lat":48,"lon":47},[51],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},{"type":24,"investigatorFullName":23,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Chief physician",[55],{"name":56,"class":6},"Peking University Cancer Hospital & Institute","100555099","evaluate-the-efficacy-and-safety-of-radiotherapy-combined-with-ripretinib-in-the-treatment-of-unresectable-advanced-gist-100555099",false,"NCT06507683","Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST","A Multicenter, Single-arm, Prospective Study to Evaluate the Efficacy and Safety of Radiotherapy Combined With Ripretinib in the Treatment of Unresectable Advanced GIST","Inclusion Criteria:\n\n* Voluntary participation and signed informed consent;\n* age: 18 to 75 years, Male or female\n* Patients with histologically confirmed GIST and Imaging evaluated as unresectable recurrent and metastatic disease or locally advanced.\n* ECOG Performance Score: 0-2\n* Subjects who have progressed or documented intolerance after previous first-line, second-line, and third-line treatments.\n* At least one measurable lesion in the abdominal or pelvic cavity that has progressed after frontline treatment\n* Adequate organ function and bone marrow reserve\n\nExclusion Criteria:\n\n* estimated life-expectancy less than 3 months.\n* Patients who have received previous radiotherapy to the proposed radiotherapy site, or the tumor has significant mobility, poor tolerance of radiotherapy in adjacent organs, and who are considered unsuitable for radiotherapy after MDT discussion\n* Any other clinically significant comorbidities, which in the judgment of the investigator, could compromise compliance with the protocol, interfere with interpretation of the study results, or predispose the patient to safety risks.\n* If female, the patient is pregnant or lactating, or plans to become pregnant during the study treatment period","ALL","18 Years","75 Years",{"count":68,"type":69},32,"ESTIMATED","INTERVENTIONAL",[72],"NA","The goal of this prospective study is to learn whether there is a synergistic effect when radiotherapy is combined with ripretinib in the treatment of patients with unresectable advanced GIST. It will also learn about the safety of this regimen.The main questions it aim to answer is: Dose radiotherapy combined with ripretinib prolong the time to disease progression for patients with advanced GIST?",[75],"Gastrointestinal Stromal Tumors","2024-07-12",{"date":78,"type":79},"2024-07-18","ACTUAL",{"date":81,"type":79},"2024-05-28",{"date":83,"type":69},"2027-07",{"name":5,"class":6},1]